Drug Giant Bristol Partners with Illumina on Diagnostic Test to Use with UpdivoBristol-Myers Squibb is partnering with Illumina to develop diagnostic tests that will pair with Bristol’s oncology immunotherapies. 

The companies plan to develop a diagnostic version of the Illumina TruSight Oncology 500 assay to measure potentially predictive biomarkers, including Tumour Mutation Burden (TMB). 

The partnership expands Illumina’s oncology offerings for NextSeq 550Dx. 

Bristol-Myers Squibb’s clinical development program includes 24 clinical-stage molecules designed to target different immune system pathways across more than 50 types of cancers, and through its translational capabilities, has identified a number of potentially predictive biomarkers, including PD-L1, TMB, MSI-H/dMMR and LAG-3.

 

Loxo and Illumina Partner Up for Diagnostic Tool Targeting Cancer

 

“Through our deep understanding of cancer biology and emerging research, we recognize the importance for physicians to know each patient’s biomarker status to help fight their cancer in a more personalized way,” said Saurabh Saha, a Bristol Senior Vice President, in the press release.

Garret Hampton, Illumina’s EVP of clinical genomics added: “With BMS’ leading position in immunotherapy development, we see tremendous promise in this partnership to co-develop next-generation sequencing-based diagnostics that can identify effective therapeutic combinations and provide global access to these targeted drugs.”